50919-06-7

Basic information

• Product Name: 2-FLUOROPHENETHYL ALCOHOL
• Synonyms: 2-FLUOROPHENETHYL ALCOHOL;2-(O-FLUOROPHENYL)ETHANOL;1-fluoro-2-(2-hydroxyethyl)benzene;2-(2-fluorophenyl)ethanol;2-Fluorophenethyl alcohol 99%;2-Fluorophenethyl alcohol,99%;2-(2-Fluorophenyl)ethyl alcohol;2-fluoro-2-phenylethan-1-ol
• CAS NO: 50919-06-7
• Molecular Formula: C₈H₉FO
• Molecular Weight: 140.15
• Product Categories: Alcohols;C7 to C8;Oxygen Compounds;Fluorine series
• Mol File: 50919-06-7.mol

Chemical Properties

• Boiling Point: 72°C 1mm
• Flash Point: 209 °F
• Appearance: Clear colorless/Liquid
• Density: 1.045 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.133mmHg at 25°C
• Refractive Index: n20/D 1.509(lit.)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.68±0.10(Predicted)
• CAS DataBase Reference: 2-FLUOROPHENETHYL ALCOHOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-FLUOROPHENETHYL ALCOHOL(50919-06-7)
• EPA Substance Registry System: 2-FLUOROPHENETHYL ALCOHOL(50919-06-7)

Safety Data

• Hazard Codes: Xn,Xi,C
• Statements: 36/37/38-21/22-34
• Safety Statements: 36/37/39-26-45-27-37-23
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 50919-06-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Fluorophenethyl alcohol is used as a synthetic intermediate for the preparation of phenethyl ester derivative analogs of the C-terminal tetrapeptide of gastrin. These analogs act as potent gastrin antagonists, which can be utilized in the development of drugs targeting gastrin-related conditions, such as gastrointestinal disorders and certain types of cancers.
The unique chemical properties of 2-Fluorophenethyl alcohol, particularly the presence of the fluorine atom, make it an attractive candidate for the synthesis of various biologically active compounds. Its application in the pharmaceutical industry highlights its potential in contributing to the development of novel therapeutic agents.

InChI:InChI=1/C8H9FO/c9-8-4-2-1-3-7(8)5-6-10/h1-4,10H,5-6H2

Upstream product

• 584-74-7 o-fluorophenylacetic acid ethyl ester 
• 451-82-1 (2-fluorophenyl)acetic acid 
• 394-46-7 2-fluorostyrene 
• 57486-67-6 methyl o-fluorophenylacetate 
• 766-49-4 (2-fluorophenyl)acetylene 

Downstream Products

• 549503-57-3 2-(2-fluorophenyl)ethyl diisopropylcarbamate 
• 883439-25-6 1-Fluoro-2-(2-vinyloxyethyl)-benzene 
• 478163-05-2 4-(2-(2-fluorophenyl)ethoxy)acetophenone 
• 877149-83-2 3-(2-fluorophenyl)propanenitrile 
• 91319-54-9 1-(2-bromoethyl)-2-fluorobenzene 
• 267643-66-3 toluene-4-sulfonate-2-(2-fluoro-phenyl)-ethyl ester 
• 119779-12-3 2-fluorophenylethyl chloride 

Relevant articles and documents

NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Discovery, synthesis, and structure-activity relations of 3,4-dihydro-1H-spiro(naphthalene-2,2′-piperidin)-1-ones as potassium-competitive acid blockers

With the aim to discover a gastric antisecretory agent more potent than the existing proton pump inhibitors, novel 3,4-dihydro-1H-spiro(naphthalene-2,2′-piperidin)-1-one derivatives, which could occupy two important lipophilic pockets (described as LP-1 and LP-2) of H+,K+-ATPase and can strongly bind to the K+-binding site, were designed based on a docking model. Among the compounds synthesized, compound 4d showed a strong H+,K+-ATPase-inhibitory activity and a high stomach concentration in rats, resulting in potent inhibitory action on histamine-stimulated gastric acid secretion in rats. Furthermore, 4d exerted significant inhibitory action on histamine-stimulated gastric-acid secretion in rats with a rapid onset and moderate duration of action after the administration. These findings may lead to a new insight into the drug design of potassium-competitive acid blockers.

Antiproliferative activity and SARs of caffeic acid esters with mono-substituted phenylethanols moiety

A series of CAPE derivatives with mono-substituted phenylethanols moiety were synthesized and evaluated by MTT assay on growth of 4 human cancer cell lines (Hela, DU-145, MCF-7 and ECA-109). The substituent effects on the antiproliferative activity were systematically investigated for the first time. It was found that electron-donating and hydrophobic substituents at 2′-position of phenylethanol moiety could significantly enhance CAPE's antiproliferative activity. 2′-Propoxyl derivative, as a novel caffeic acid ester, exhibited exquisite potency (IC50?=?0.4?±?0.02 & 0.6?±?0.03?μM against Hela and DU-145 respectively).

Temporal separation of catalytic activities allows anti-Markovnikov reductive functionalization of terminal alkynes

There is currently great interest in the development of multistep catalytic processes in which one or several catalysts act sequentially to rapidly build complex molecular structures. Many enzymes - often the inspiration for new synthetic transformations - are capable of processing a single substrate through a chain of discrete, mechanistically distinct catalytic steps. Here, we describe an approach to emulate the efficiency of these natural reaction cascades within a synthetic catalyst by the temporal separation of catalytic activities. In this approach, a single catalyst exhibits multiple catalytic activities sequentially, allowing for the efficient processing of a substrate through a cascade pathway. Application of this design strategy has led to the development of a method to effect the anti-Markovnikov (linear-selective) reductive functionalization of terminal alkynes. The strategy of temporal separation may facilitate the development of other efficient synthetic reaction cascades.

A highly active and air-stable ruthenium complex for the ambient temperature anti-markovnikov reductive hydration of terminal alkynes

The conversion of terminal alkynes to functionalized products by the direct addition of heteroatom-based nucleophiles is an important aim in catalysis. We report the design, synthesis, and mechanistic studies of the half-sandwich ruthenium complex 12, which is a highly active catalyst for the anti-Markovnikov reductive hydration of alkynes. The key design element of 12 involves a tridentate nitrogen-based ligand that contains a hemilabile 3-(dimethylamino) propyl substituent. Under neutral conditions, the dimethylamino substituent coordinates to the ruthenium center to generate an air-stable, 18-electron, κ3-complex. Mechanistic studies show that the dimethylamino substituent is partially dissociated from the ruthenium center (by protonation) in the reaction media, thereby generating a vacant coordination site for catalysis. These studies also show that this substituent increases hydrogenation activity by promoting activation of the reductant. At least three catalytic cycles, involving the decarboxylation of formic acid, hydration of the alkyne, and hydrogenation of the intermediate aldehyde, operate concurrently in reactions mediated by 12. A wide array of terminal alkynes are efficiently processed to linear alcohols using as little as 2 mol % of 12 at ambient temperature, and the complex 12 is stable for at least two weeks under air. The studies outlined herein establish 12 as the most active and practical catalyst for anti-Markovnikov reductive hydration discovered to date, define the structural parameters of 12 underlying its activity and stability, and delineate design strategies for synthesis of other multifunctional catalysts.

Regioselective reductive hydration of alkynes to form branched or linear alcohols

The regioselective reductive hydration of terminal alkynes using two complementary dual catalytic systems is described. Branched or linear alcohols are obtained in 75-96% yield with ?25:1 regioselectivity from the same starting materials. The method is compatible with terminal, di-, and trisubstituted alkenes. This reductive hydration constitutes a strategic surrogate to alkene oxyfunctionalization and may be of utility in multistep settings.

SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions (formula (I)).

Exploiting self-assembly for ligand-scaffold optimization: Substrate-tailored ligands for efficient catalytic asymmetric hydroboration

(Chemical Equation Presented) Mix and match: A self-assembled ligand library (SAL XY) affords a wide range of R/S ratios in Rh-catalyzed asymmetric hydroboration (see scheme; nbd = 2,5-norbornadiene, R* is a chiral substituent). Ligand-scaffold optimization reveals "substrate- tailored" ligands that afford high regio- and enantioselectivity for a variety of ortho-substituted styrene derivatives.

Regioselective hydroboration-oxidation and -amination of fluoro-substituted styrenes

Hydroboration of fluorinated styrenes with common hydroborating agents results in polymerization. However, regioselective hydroboration has been achieved by utilizing iodoborane-dimethyl sulfide. A series of fluorinated β-phenethyl alcohols and amines were synthesized via this methodology.

4-aminocyclohexanol deriv. substd.

4-aminocyclohexanol compounds, processes for their preparation, pharmaceutical formulations comprising these compounds and the use of substituted 4-aminocyclohexanol compounds for the preparation of pharmaceutical formulations and for the treatment of diverse indications, including, without limitation, pain.